BiotechTube

JR-141

Phase 2Active
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Mucopolysaccharidosis II

Conditions

Mucopolysaccharidosis II

Trial Timeline

Jan 1, 2019 → Dec 31, 2027

NCT ID
NCT03708965

About JR-141

JR-141 is a phase 2 stage product being developed by JCR Pharmaceuticals for Mucopolysaccharidosis II. The current trial status is active. This product is registered under clinical trial identifier NCT03708965. Target conditions include Mucopolysaccharidosis II.

What happened to similar drugs?

5 of 15 similar drugs in Mucopolysaccharidosis II were approved

Approved (5) Terminated (1) Active (10)
✅laronidaseSanofiApproved
✅LaronidaseSanofiApproved
✅Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiApproved
✅LaronidaseSanofiApproved
✅NaglazymeBioMarin PharmaceuticalApproved
🔄Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiPhase 3
🔄rhIDU (recombinant human-Alpha-L-Iduronidase) + PlaceboSanofiPhase 3

Hype Score Breakdown

Clinical
12
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (5)

NCT IDPhaseStatus
NCT05594992Phase 3Recruiting
NCT04348136Phase 2/3Active
NCT03708965Phase 2Active
NCT03568175Phase 2/3Completed
NCT03128593Phase 1/2Completed

Competing Products

20 competing products in Mucopolysaccharidosis II

See all competitors
ProductCompanyStageHype Score
OdiparcilInventivaPhase 2
29
anakinraSwedish Orphan BiovitrumPhase 1/2
32
laronidaseSanofiApproved
43
LaronidaseSanofiApproved
43
Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiPhase 2
35
Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiApproved
43
Laronidase + Cyclosporine A (CsA) + Azathioprine (Aza)SanofiPhase 1/2
32
Aldurazyme (Recombinant Human Alpha-L-Iduronidase)SanofiPhase 3
40
rhIDU (recombinant human-Alpha-L-Iduronidase) + PlaceboSanofiPhase 3
40
Aldurazyme + Aldurazyme + placeboSanofiPhase 3
40
LaronidaseSanofiApproved
35
JR-141JCR PharmaceuticalsPhase 2/3
38
JR-441 + JR-441 + JR-441JCR PharmaceuticalsPhase 1/2
36
JR-446JCR PharmaceuticalsPhase 1/2
39
JR-171JCR PharmaceuticalsPhase 1/2
32
JR-141 + Idursulfase + JR-141 or IdursulfaseJCR PharmaceuticalsPhase 3
44
JR-141JCR PharmaceuticalsPhase 3
47
JR-171 (lepunafusp alfa)JCR PharmaceuticalsPhase 1/2
32
JR-141JCR PharmaceuticalsPhase 1/2
32
JR-141JCR PharmaceuticalsPhase 2/3
42